FSGS MCP-1 individual patient data supports my concern that only 1 or 2 "extreme" patients have exaggerated the efficacy signal since that is only shown as averages
Ann: Positive Additional Data to Support DMX-200 Development, page-18
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $220.1M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.0¢ | $199.7K | 504.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14825 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 43936 | 5 |
View Market Depth
| Last trade - 12.12pm 01/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |